Taylor Hoffman Wealth Management Has $637,000 Holdings in Becton Dickinson and Co (BDX)

Share on StockTwits

Taylor Hoffman Wealth Management raised its position in Becton Dickinson and Co (NYSE:BDX) by 5.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,895 shares of the medical instruments supplier’s stock after acquiring an additional 159 shares during the quarter. Taylor Hoffman Wealth Management’s holdings in Becton Dickinson and were worth $637,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in BDX. CWM LLC increased its position in shares of Becton Dickinson and by 5.6% during the fourth quarter. CWM LLC now owns 830 shares of the medical instruments supplier’s stock valued at $187,000 after buying an additional 44 shares during the period. Mitchell Mcleod Pugh & Williams Inc. increased its position in shares of Becton Dickinson and by 1.2% during the fourth quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 4,123 shares of the medical instruments supplier’s stock valued at $929,000 after buying an additional 47 shares during the period. Abner Herrman & Brock LLC increased its position in shares of Becton Dickinson and by 4.5% during the fourth quarter. Abner Herrman & Brock LLC now owns 1,105 shares of the medical instruments supplier’s stock valued at $249,000 after buying an additional 48 shares during the period. Providence Capital Advisors LLC increased its position in shares of Becton Dickinson and by 0.5% during the fourth quarter. Providence Capital Advisors LLC now owns 10,240 shares of the medical instruments supplier’s stock valued at $2,307,000 after buying an additional 48 shares during the period. Finally, Ledyard National Bank increased its position in shares of Becton Dickinson and by 2.3% during the fourth quarter. Ledyard National Bank now owns 2,268 shares of the medical instruments supplier’s stock valued at $511,000 after buying an additional 50 shares during the period. Hedge funds and other institutional investors own 83.84% of the company’s stock.

BDX has been the topic of several research analyst reports. Citigroup reduced their price target on shares of Becton Dickinson and from $289.00 to $279.00 and set a “buy” rating on the stock in a research report on Tuesday, November 13th. Wells Fargo & Co reduced their price target on shares of Becton Dickinson and from $290.00 to $280.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 7th. Barclays set a $260.00 price target on shares of Becton Dickinson and and gave the company a “hold” rating in a research report on Thursday, November 8th. UBS Group initiated coverage on shares of Becton Dickinson and in a research report on Tuesday, November 27th. They set a “neutral” rating and a $260.00 price target on the stock. Finally, Deutsche Bank initiated coverage on shares of Becton Dickinson and in a research report on Thursday, December 6th. They set a “buy” rating and a $280.00 price target on the stock. Six analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $253.17.

Shares of BDX opened at $242.21 on Friday. The stock has a market capitalization of $64.99 billion, a price-to-earnings ratio of 22.00, a price-to-earnings-growth ratio of 1.70 and a beta of 1.23. The company has a debt-to-equity ratio of 0.83, a quick ratio of 0.69 and a current ratio of 0.97. Becton Dickinson and Co has a fifty-two week low of $208.62 and a fifty-two week high of $265.87.

Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Tuesday, February 5th. The medical instruments supplier reported $2.70 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.58 by $0.12. The business had revenue of $4.16 billion for the quarter, compared to analysts’ expectations of $4.10 billion. Becton Dickinson and had a net margin of 5.69% and a return on equity of 14.65%. The business’s revenue was up 35.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.48 earnings per share. As a group, equities analysts predict that Becton Dickinson and Co will post 12.1 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 29th. Shareholders of record on Friday, March 8th will be issued a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a yield of 1.27%. The ex-dividend date of this dividend is Thursday, March 7th. Becton Dickinson and’s dividend payout ratio (DPR) is presently 27.97%.

In other Becton Dickinson and news, insider Thomas E. Polen, Jr. sold 5,243 shares of the company’s stock in a transaction dated Monday, November 19th. The shares were sold at an average price of $243.86, for a total value of $1,278,557.98. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, SVP Charles R. Bodner sold 2,080 shares of the company’s stock in a transaction dated Friday, November 16th. The stock was sold at an average price of $245.83, for a total transaction of $511,326.40. Following the completion of the sale, the senior vice president now owns 4,497 shares in the company, valued at approximately $1,105,497.51. The disclosure for this sale can be found here. In the last 90 days, insiders sold 34,606 shares of company stock worth $8,356,772. Corporate insiders own 0.12% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This news story was reported by Macon Daily and is owned by of Macon Daily. If you are viewing this news story on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The legal version of this news story can be read at https://macondaily.com/2019/02/09/taylor-hoffman-wealth-management-has-637000-holdings-in-becton-dickinson-and-co-bdx.html.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Recommended Story: Trading signals using Bollinger bands

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply